{"id":10936,"date":"2024-06-17T00:41:17","date_gmt":"2024-06-17T00:41:17","guid":{"rendered":"https:\/\/investors-admin.raizinvest.com.au\/?p=10936"},"modified":"2024-06-19T02:13:36","modified_gmt":"2024-06-19T02:13:36","slug":"fisher-paykel-healthcare-share-price-jumps","status":"publish","type":"post","link":"https:\/\/raizinvest.com.au\/investors\/blog\/fisher-paykel-healthcare-share-price-jumps\/","title":{"rendered":"Fisher & Paykel Healthcare share price jumps, mining stock South 32 looms as a watch for investors"},"content":{"rendered":"
\n
\n

\"\"<\/p>\n

One of the ASX\u2019s leading healthcare stocks has returned to its 52-week highs as investors pile in after its May earnings results.<\/p>\n

Fisher & Paykel Healthcare is up over 29 per cent over the last 12 months with its stock hovering close to its 52-week high at $28 per share as of Thursday. The company released its results at the end of May and announced a slightly higher dividend, along with stronger forward guidance. The company is set to pay a final dividend of 23.5 NZ cents per share, up half a cent on last year, as it expects net profit after tax up to $360 million in the next financial year.<\/p>\n

This boosted trading activity on Raiz by 751 per cent to over, 600 shares traded. This is an 853 per cent increase over the month when there were fewer than 300 shares traded.<\/p>\n

Also steamrolling forward this week on Raiz was mining stock South 32 ($32), which had a 422 per cent increase in trades this week. It\u2019s been a strong stock over the month, despite coming down a bit off its highs in May.<\/p>\n

Macquarie analysts this week listed this miner as a top stock and labelled it as a buy due to its exposure to copper. Analysts expect it to outperform with a price target of $4.25 while it currently sits around $3.65. This would represent a potential upside of close to 16 per cent for investors over the next 12 months.<\/p>\n

\"\"<\/p>\n

\n

Sneaking into the Raiz top 10 list this week was the Goodman Group which saw an 143 per cent increase in shares traded. There were just over 1500 shares traded, however, this represents a massive 2000 per cent increase over the last four weeks.<\/p>\n<\/div>\n

\n

It was one of the top-performing stocks last week, up over 5 per cent but there\u2019s been a fair bit of media noise around the stock over the past week. Motley Fool marked it as one of their high-quality stocks to hold forever, given its portfolio of assets globally. It also has exposure to AI through its data centre pipeline which is likely to be a key driver of future growth. It can also benefit from the current warehouse shortage as it expects to grow its operating earnings per share by 13% in FY24.<\/p>\n<\/div>\n

\n

AMP has remained the top stock on Raiz with over 11,200 shares traded however it\u2019s been slipping down each week. This week it\u2019s down over 20 per cent and it\u2019s down over 30 per cent from its high back in May. It still remains a market leader but that margin does continue to narrow.<\/p>\n<\/div>\n

\n
\n

ETFs were a mixed bag this week, after last week\u2019s bonanza of increases. Despite the mixed bag, the top two ETFs were able to bring up overall units traded by 2 per cent. Those two ETFs were the Russell Investments Australian Select Corporate Bond and the SPDR S&P ASX 200 which regularly feature in the top 10. They were up 6 per cent and 8 per cent respectively.<\/p>\n<\/div>\n

\n

The real ETF leader this week was iShares Europe, which provides investors with the performance of the S&P Europe 350 TM Index. This company features a range of leading blue-chip companies including Shell, Novartis and even AstraZeneca.<\/p>\n<\/div>\n

\n

Meanwhile, many of the ETFs lost some shine with the biggest laggard being the iShares Asia 50. It saw a 9.5 per cent drop in units traded as it dropped down to 35,000 units traded.<\/p>\n<\/div>\n

\n

It has been trading near the 30,000 mark for the last few weeks so the slight drop may just represent a return to regular levels.<\/p>\n

 <\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n

This article was originally published on The Nightly website here<\/strong><\/a>.<\/p>\n<\/div>\n

\n

 <\/p>\n

Published 14\/6\/2024<\/em><\/p>\n

 <\/p>\n

Don\u2019t have the Raiz App?<\/h3>\n

Download it for free in the App store or the Webapp below:<\/p>\n

\n

\"download-raiz-app\"<\/a>
Click to download the Raiz app<\/a><\/span><\/figcaption><\/figure><\/figure>\n

 <\/p>\n

Important Information<\/em><\/strong><\/p>\n

Raiz Invest Australia Limited \u2013 Authorised Representative of AFSL 434776. The Raiz Invest Australia Fund and Raiz Property Fund are issued in Australia by Instreet Investment Limited (ACN 128 813 016 AFSL 434776) a subsidiary of Raiz Invest Limited and promoted by Raiz Invest Australia Limited (ACN 604 402 815).<\/em><\/p>\n

Raiz Invest Super is a Division of AMG Super and is issued by Equity Trustees Superannuation Limited (AFSL 229757, RSE Licence No L0001458) as Trustee of AMG Super.<\/em><\/p>\n

T<\/span>he information is general information only and does not <\/span>take into account<\/span> of your personal financial situation, <\/span>goals<\/span> or needs. You should obtain financial advice tailored to your circumstances by a licensed <\/span>financial <\/span>adviser<\/span>.<\/span><\/span>\u00a0<\/span><\/em><\/p>\n

A Product Disclosure Statement (PDS<\/strong>) and Target Market Determination (TMD<\/strong>) for Raiz Invest Australia Fund, Raiz Invest Super and Raiz Property Fund (together, the Products<\/strong>) are available on the Raiz Invest website and App. Please read and consider the PDS and TMD to understand the risks and determine if the Products are suitable for you. The risks and fees are fully set out in the PDS and include the risks that would ordinarily apply to investing.<\/em><\/p>\n

Any returns shown or implied are not forecasts and are not reliable guides or predictors of future performance.<\/em><\/p>\n

Under no circumstance is the information to be used by, or presented to, a person for the purposes of deciding about investing in the Products.<\/em><\/p>\n

This information may be based on assumptions or market conditions which change without notice and have not been independently verified.<\/em><\/p>\n

Any opinions or information expressed are subject to change without notice.<\/em><\/p>\n

Home loans are subject to approval from the lending institution and Raiz Home Ownership makes no warranties as to the success of an application until all relevant information has been provided.<\/em><\/p>\n

Raiz Home Ownership Pty Ltd (ABN 14 645 876 937), an Australian Credit Representative number 528594 under Australian Credit Licence number 387025. Raiz Home Ownership Pty Ltd is 100% owned by Raiz Invest Australia Limited (ABN 26 604 402 815).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

One of the ASX\u2019s leading healthcare stocks has returned to its 52-week highs as investors pile in after its May earnings results. Fisher & Paykel Healthcare is up over 29 per cent over the last 12 months with its stock hovering close to its 52-week high at $28 per share as of Thursday.<\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false},"categories":[1],"tags":[],"yst_prominent_words":[]}